West Pharmaceutical(US:WST) Prnewswire·2025-04-24 10:00Core Insights - West Pharmaceutical Services, Inc. reported solid financial results for Q1 2025, with revenues and adjusted-diluted EPS exceeding guidance [3][10] - The company is optimistic about continuing positive trends and is actively monitoring political and macroeconomic impacts [3] Financial Performance - Net sales for Q1 2025 were $698.0 million, a 0.4% increase from $695.4 million in Q1 2024 [10][19] - Adjusted-diluted EPS for Q1 2025 was $1.45, down from $1.56 in the same period last year [10][24] - Operating cash flow increased by 9.5% to $129.4 million, while free cash flow rose to $58.1 million from $27.6 million in Q1 2024 [7][30] Segment Performance - Proprietary Products Segment net sales grew by 0.6% to $563.0 million, with organic growth of 2.4% [4][21] - Contract-Manufactured Products Segment net sales declined by 0.7% to $135.0 million, but organic sales grew by 0.8% [6][21] Market Insights - The Biologics market unit experienced mid-single digit organic net sales growth, primarily from self-injection device platforms [5] - The Pharma market unit also saw mid-single digit organic growth, driven by standard and Westar® products [5] Guidance and Dividends - The company raised its full-year 2025 net sales guidance to a range of $2.945 billion to $2.975 billion [10][11] - Adjusted-diluted EPS guidance for 2025 was increased to a range of $6.15 to $6.35 [10][17] - A third-quarter 2025 dividend of $0.21 per share was declared, payable on August 6, 2025 [10]